AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06715670
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
AZD5305 hADME in Patients With Advanced Solid Malignancies
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumor
- Interventions
- Drug: Saruparib (AZD5305)Drug: [14C]-AZD5305 microtracerDrug: [14C]-AZD5305 (therapeutic dose)
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06713369
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
Recruiting
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT06712563
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
Phase 3
Recruiting
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 180
- Registration Number
- NCT06706817
- Locations
- 🇪🇸
Research Site, Santiago de Compostela, Spain
A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Japanese Participants and Participants With Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Healthy ParticipantsType 2 Diabetes
- Interventions
- Drug: AZD5004(Part A)Drug: Placebo(Part A)Drug: AZD5004(Part B)Drug: Placebo(Part B)
- First Posted Date
- 2024-11-25
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT06703658
- Locations
- 🇯🇵
Research Site, Osaka-shi, Japan
A Study in Patients With Myasthenia Gravis in China
Recruiting
- Conditions
- Myasthenia Gravis
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT06700616
- Locations
- 🇨🇳
Research Site, Wuhan, China
This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE
Completed
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06698900
- Locations
- 🇧🇷
Research Site, Sao Paulo, Brazil
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Phase 3
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 880
- Registration Number
- NCT06692738
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
Phase 1
Completed
- Conditions
- Renal ImpairmentEnd-stage Kidney DiseaseHealthy Participants
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT06693765
- Locations
- 🇷🇴
Research Site, Bucuresti, Romania
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Phase 2
Completed
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 202
- Registration Number
- NCT06692764
- Locations
- 🇺🇸
Research Site, Paris, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath